The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Showing 1-12 of 12 articles
A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-1 first-in-human study
Haude M,
Wlodarczak A,
van der Schaaf R,
Torzewski J,
Ferdinande B,
Escaned J,
Iglesias JF,
Bennett J,
Toth G,
Joner M,
Toelg R,
Wiemer M,
Olivecrano G,
Vermeersch P,
Garcia-Garcia H,
Waksman R
May 17, 2023 | 10.4244/EIJ-D-23-00326
Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial
Kerkmeijer L,
Renkens M,
Tijssen R,
Hofma S,
van der Schaaf R,
Arkenbout EK,
Weevers A,
Garcia-Garcia H,
Kraak R,
Piek J,
Tijssen J,
Henriques J,
de Winter R,
Wykrzykowska JJ
March 18, 2022 | 10.4244/EIJ-D-21-00419
Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial
Kraak R,
Tijssen R,
van Dongen I,
Elias J,
Hofma S,
van der Schaaf R,
Arkenbout EK,
Weevers A,
Tijssen J,
Piek J,
de Winter R,
Henriques J,
Wykrzykowska JJ
December 4, 2020 | 10.4244/EIJ-D-18-00884
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial
Kerkmeijer L,
Tijssen R,
Hofma S,
van der Schaaf R,
Arkenbout K,
Kraak R,
Weevers A,
Piek J,
de Winter R,
Tijssen J,
Henriques J,
Wykrzykowska JJ,
Ijsselmuiden A,
Kauer F,
Beijk M,
Vis MM,
Koch K
September 20, 2019 | 10.4244/EIJ-D-19-00325
Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI
Tijssen R,
Kraak R,
Hofma S,
van der Schaaf R,
Arkenbout EK,
Weevers A,
Elias J,
van Dongen I,
Koch K,
Baan Jr J,
Vis MM,
de Winter R,
Piek J,
Tijssen J,
Henriques J,
Wykrzykowska JJ
July 20, 2018 | 10.4244/EIJ-D-18-00335
Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions
Teeuwen K,
Van den Branden B,
Koolen J,
van der Schaaf R,
Henriques J,
Thijssen J,
Kelder J,
Vermeersch P,
Rensing B,
Suttorp MJ
March 20, 2015 | 10.4244/EIJY14M08_07
Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam (PAPPA): one-year clinical outcome of a pilot study
Vos N,
Dirksen M,
Vink M,
van Nooijen F,
Amoroso G,
Herrman JP,
Kiemeneij F,
Patterson M,
Slagboom T,
van der Schaaf R
September 28, 2014 | 10.4244/EIJV10I5A101
Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions
Van den Branden B,
Teeuwen K,
Koolen J,
van der Schaaf R,
Henriques J,
Thijssen J,
Kelder J,
Vermeersch P,
Rensing B,
Suttorp MJ
November 29, 2013 | 10.4244/EIJV9I7A138
Latest news
AHEAD OF PRINT
Ostial RCA ISR: mechanisms and treatment outcomes
FREE ARTICLE - Kei Yamamoto et al
June 7, 2023
AHEAD OF PRINT
Two-year outcomes after TMVR
FREE ARTICLE - Sebastian Ludwig et al
May 26, 2023
NEW ISSUE
Expert Review on Calcified CTOs; Calcified Nodules Revascularisation Debate; CTO PCI; Stent Failure and Calcified Nodules and more...
June 5, 2023
AHEAD OF PRINT
BIOSOLVE-IV registry
FREE ARTICLE - Adrian Wlodarczak et al
May 24, 2023
AHEAD OF PRINT EUROPCR
The EURO SHOCK Trial
FREE ARTICLE - Amerjeet Singh Banning et al
May 19, 2023
AHEAD OF PRINT EUROPCR
Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve (DurAVR)
FREE ARTICLE - Susheel K. Kodali et al
May 19, 2023
AHEAD OF PRINT EUROPCR
TAVI for bicuspid aortic valves with Evolut platform
FREE ARTICLE - Didier Tchétché et al
May 18, 2023